氢可酮盐酸盐 | 25968-91-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 中文名称: 氢可酮盐酸盐
• 中文别名: 盐酸氢可酮
• 英文名称: Hydrocodone hydrochloride
• 英文别名: dihydrocodeinone hydrochloride；7,8-dihydrocodeinone hydrochloride；4,5α-epoxy-3-methoxy-17-methyl-morphinan-6-one; hydrochloride；4,5α-Epoxy-3-methoxy-17-methyl-morphinan-6-on; Hydrochlorid；oxycontin；(4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
• CAS: 25968-91-6
• 化学式: C₁₈H₂₁NO₃*ClH
• 分子量: 335.831
• InChiKey: GCJAEXSZUXBMFS-RNWHKREASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  38.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  氢可酮盐酸盐 在 diethylaminosulfur trifluoride 作用下， 生成 17-Methyl-6,7-dihydro-4-hydroxy-5-chloro-6-fluoro-3-methoxymorphinan Hydrochloride
  参考文献：
  名称：

  Fluoro analogs of hydrocodone and oxycodone useful as analgesics,

  摘要：

  6-氟羟考酮和羟考酮的类似物是镇痛剂和/或麻醉拮抗剂。例如，17-环丙基甲基-4,5-环氧-6,6-二氟-3-甲氧吗啡和17-环丙基甲基-6,7-二去氢-4,5-环氧-6-氟-3-甲氧基和-3-乙酰氧基吗啡。

  公开号：

  US04241065A1
• 作为产物：
  描述：

  二氢可待因酮 在 盐酸 作用下， 以 水 、 异丙醇 为溶剂， 生成 氢可酮盐酸盐
  参考文献：
  名称：

  Preparation of Saturated Ketone Morphinan Compounds by Catalytic Isomerization

  摘要：

  本发明提供了通过催化异构化制备饱和酮吗啡类化合物的方法。具体而言，该发明提供了一种将含有烯丙醇环基团的吗啡类化合物转化为含有饱和酮环基团的吗啡类化合物的方法，该方法通过由烯丙基过渡金属催化剂催化的异构化反应实现。

  公开号：

  US20100261904A1

文献信息

• [EN] POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE<br/>[FR] PROMÉDICAMENTS D'OPIOÏDES À SOUS-UNITÉS MULTIPLES RÉSISTANTS AUX SURDOSES ET AUX ABUS
  申请人：ELYSIUM THERAPEUTICS INC

  公开号：WO2018170465A1

  公开（公告）日：2018-09-20

  The invention provides compositions and methods for the treatment or prevention of pain. Compositions provided are resistant to overdose and abuse. Compositions provided comprise two or more different molecules, where each molecule comprises at least one GI enzyme-labile opioid agonist releasing subunit comprising an opioid agonist that is covalently linked to at least one GI enzyme inhibitor subunit.

  这项发明提供了用于治疗或预防疼痛的组合物和方法。所提供的组合物具有抗过量和滥用的特性。所提供的组合物包括两种或两种以上不同的分子，其中每种分子至少包括一个至少含有一个胃肠酶敏感的阿片类受体激动剂释放亚基的阿片类受体激动剂，该阿片类受体激动剂与至少一个胃肠酶抑制剂亚基共价连接。
• BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF
  申请人：Mickle Travis

  公开号：US20110002990A1

  公开（公告）日：2011-01-06

  The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了包含芳基羧酸与羟考酮（吗啡酮-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）化学共轭形成的新型羟考酮前药/组合物，包括苯甲酸酯和杂环芳基羧酸，具有降低滥用羟考酮潜力的特性。该技术还提供了治疗患者的方法、制药工具包和合成本技术共轭物的方法。
• [EN] PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS OF HYDROCODONE BENZOIC ACID ENOL ESTER AND PROCESSES FOR MAKING SAME<br/>[FR] SELS PHARMACEUTIQUEMENT ACCEPTABLES ET FORMES POLYMORPHES DE L'ESTER ÉNOLIQUE DE L'ACIDE HYDROCODONE BENZOÏQUE ET LEURS PROCÉDÉS DE FABRICATION
  申请人：JOHNSON MATTHEY PLC

  公开号：WO2014138740A1

  公开（公告）日：2014-09-12

  Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.

  包括羟考酮苯甲酸烯醇酯在内的组合物，形成包括羟考酮苯甲酸烯醇酯盐和各种多型体的新型前药。还提供了制备羟考酮苯甲酸烯醇酯盐和各种多型体的方法。
• [EN] IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS<br/>[FR] COMPOSITIONS ANTI-ABUS À LIBÉRATION IMMÉDIATE OU MÉDICAMENTS DESTINÉS AU TRAITEMENT DE LA DOULEUR, DU DCA, DU TDAH, ET D'AUTRES SYNDROMES OU TROUBLES
  申请人：KEMPHARM INC

  公开号：WO2018071879A1

  公开（公告）日：2018-04-19

  The presently described technology provides one or more compositions, preferably one or more immediate-release profile compositions, comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5- alpha-epoxy-3-methoxy-17-methyl), or chemically conjugated to hydromorphone (4,5,α-epoxy-3-hydroxy-17-methyl morphinan-6-one), in combination with at least one gel forming polymer; at least one disintegrant; and at least one surfactant to form novel compositions which have a decreased potential for abuse. The hydrocodone conjugate can also be combined with an analgesic, such as acetaminophen, to form a combinatorial composition that includes at least one gel forming polymer; at least one disintegrant; and at least one surfactant. The present technology also provides pharmaceutical kits and methods of synthesizing conjugates of the present technology.

  目前描述的技术提供了一种或多种组合物，最好是一种或多种立即释放剖面组合物，其中含有与羟考酮（吗啡-6-酮，4,5-α-环氧-3-甲氧基-17-甲基）或与羟吗啡（4,5,α-环氧-3-羟基-17-甲基吗啡-6-酮）化学结合的芳基羧酸，结合至少一种凝胶形成聚合物；至少一种崩解剂；和至少一种表面活性剂，以形成具有减少滥用潜力的新型组合物。羟考酮结合物还可以与镇痛剂（如对乙酰氨基酚）结合，形成包括至少一种凝胶形成聚合物；至少一种崩解剂；和至少一种表面活性剂的组合物。该技术还提供了药物配套组和合成本技术结合物的方法。
• Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof
  申请人：KemPharm, Inc.

  公开号：US20150335759A1

  公开（公告）日：2015-11-26

  The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

  目前描述的技术提供了治疗患有中度至严重疼痛、麻醉药或阿片类药物滥用或戒断症状的患者的方法。目前描述的方法是通过向患者施用包含对乙酰氨基酚和苯甲酸盐羟考酮盐酸盐的药物有效量的组合物来实施的。与未结合的羟考酮相比，该组合物具有减少的副作用。